Figure 9 — A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

Research Paper|Volume 9, Issue 10|pp. 2098–2116

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

Back to articleFigure 9(9 of 14)

100%

Figure 9.A short c-Myc-related mitochondrial signature predicts poor clinical outcome in high-risk ER(+) breast cancer patients. Note that this short 3-gene signature (HSPD1/COX5B/TIMM44) effectively predicts tumor recurrence and distant metastasis in ER(+)/LN(+)/luminal A patients treated with tamoxifen therapy, indicative of treatment failure and tamoxifen-resistance. RFS, recurrence-free survival; DMFS, distant metastasis-free survival.